Literature DB >> 16425360

Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.

Zaigham Abbas1, Tariq Moatter, Akber Hussainy, Wasim Jafri.   

Abstract

AIM: To investigate the association between cytokine gene polymorphism and disease status in chronic hepatitis C genotype 3 by liver biopsy, ALT, HCV RNA levels and response to treatment.
METHODS: Patients with chronic hepatitis C genotype 3 were analyzed for single nucleotide polymorphisms of interleukin (IL)-10, IL-1 beta, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) by polymerase chain reaction using sequence-specific oligonucleotide primers. Liver biopsies were assessed by modified histological activity index (HAI) scoring system using a scale of 0-18 for grading the necro-inflammatory activity and 0-6 for staging the fibrosis. HCV RNA levels were determined by bDNA assay. The patients were treated with interferon alpha and ribavirin for 6 mo. Sustained virological response was assessed 6 mo after the completion of the treatment.
RESULTS: Out of the 40 patients analyzed, 26 were males. Mean age was 40.5+/-12.5 years (range 18-65 years). The frequencies of different dimorphic polymorphisms based on single nucleotide substitution were as follows: IL-10-1082 G/A 85%, A/A 12.5%, G/G 2.5%; IL-10-819 A/C 87.5%, C/C 10%, A/A 2.5%; IL-10-592 C/A 72.5%, C/C 27.5%; IL-1 C 90%, U 10%; IFN-874 T/A 50%, T/T 27.5%, A/A 22.5%; TNF-308 A/G 95%, G/G 5%; TGF-10 T/C 52.5%, C/C 35%, T/T 12.5%. The mean grades of necro-inflammatory activity of different genotypes of IL-10 at promoter site -1082 were A/A = 3.6, A/G = 5.0, and G/G = 10.0 and the difference was significant (P = 0.029). The difference in the stage of disease at a scale of 0-6 was A/A 0.8, A/G 2.3, and G/G 4.0 (P = 0.079). The difference in the HAI seemed to be related to the presence of allele -1082G. For IL-10 -819 genotypes, mean scores of fibrosis were A/A = 6.0, A/C = 2.2, and C/C = 1.0 (P = 0.020) though the inflammatory activity was not much different. No significant differences in HAI were noted among polymorphisms of other cytokines. Moreover, ALT and HCV RNA levels were not significantly different among different cytokine polymorphisms. There was a significant correlation of HAI and HCV RNA levels with the duration of disease. TGFbeta -10 genotype CC patients had a better end of treatment response than those with other genotypes (P = 0.020). Sustained virological response to the treatment was not influenced by the cytokine polymorphism. No effect of other factors like viral load, degree of fibrosis, gender, steatosis, was observed on sustained virological response in this population infected with genotype 3.
CONCLUSION: There is no significant correlation between cytokine polymorphisms and HAI except for the polymorphisms of anti-inflammatory cytokine IL-10, which may influence hepatic inflammatory activity and fibrosis in patients with chronic hepatitis C genotype 3. Sustained virological response in this genotype does not seem to be influenced by cytokine gene polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16425360      PMCID: PMC4355760          DOI: 10.3748/wjg.v11.i42.6656

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms.

Authors:  C Perrey; S J Turner; V Pravica; W M Howell; I V Hutchinson
Journal:  Transpl Immunol       Date:  1999-06       Impact factor: 1.708

2.  Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C.

Authors:  R Fukuda; N Ishimura; S Ishihara; A Chowdhury; N Morlyama; C Nogami; T Miyake; M Niigaki; A Tokuda; S Satoh; S Sakai; S Akagi; M Watanabe; S Fukumoto
Journal:  Liver       Date:  1996-12

3.  Cytokine gene expression in cirrhotic and non-cirrhotic human liver.

Authors:  L Llorent; Y Richaud-Patin; N Alcocer-Castillejos; R Ruiz-Soto; M A Mercado; H Orozco; A Gamboa-Domínguez; J Alcocer-Varela
Journal:  J Hepatol       Date:  1996-05       Impact factor: 25.083

Review 4.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

5.  Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa.

Authors:  C J Edwards-Smith; J R Jonsson; D M Purdie; A Bansal; C Shorthouse; E E Powell
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

6.  Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection.

Authors:  K M Chang; R Thimme; J J Melpolder; D Oldach; J Pemberton; J Moorhead-Loudis; J G McHutchison; H J Alter; F V Chisari
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

7.  Interleukin 10 secretion in relation to human IL-10 locus haplotypes.

Authors:  J Eskdale; G Gallagher; C L Verweij; V Keijsers; R G Westendorp; T W Huizinga
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C.

Authors:  C Fabris; G Soardo; E Falleti; P Toniutto; D Vitulli; E Federico; M Del Forno; M Mattiuzzo; F Gonano; M Pirisi
Journal:  J Interferon Cytokine Res       Date:  1998-09       Impact factor: 2.607

9.  Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease.

Authors:  D Roulot; H Durand; T Coste; J Rautureau; A D Strosberg; R Benarous; S Marullo
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  19 in total

1.  The Impact of IFN-γ Gene Polymorphisms on Spontaneous Clearance of HCV Infection in Fars Province, Southern of Iran.

Authors:  Jamal Sarvari; Afagh Moattari; Neda Pirbonyeh; Maryam Moini; Seyed Younes Hosseini
Journal:  J Clin Lab Anal       Date:  2015-05-20       Impact factor: 2.352

2.  Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients.

Authors:  Nadia Bouzgarrou; Elham Hassen; Olfa Bahri; Sallouha Gabbouj; Nabil Ben Mami; Henda Triki; Lotfi Chouchane
Journal:  Hepatol Int       Date:  2011-02-08       Impact factor: 6.047

3.  Haplotype analysis of interleukin-10 gene promoter polymorphisms in chronic hepatitis C infection: a case control study.

Authors:  Samaneh Sepahi; Alireza Pasdar; Mitra Ahadi; Sina Gerayli; Sina Rostami; Zahra Meshkat
Journal:  Viral Immunol       Date:  2014-08-13       Impact factor: 2.257

4.  Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients.

Authors:  Yousri Mostafa Hussein; Ayman Alhazmi; Saad Alzahrani; Ahmad El-Askary; Abdulrahman Alghamdy; Eman Bayomy; Assmaa Selim; Mohammed Alghamdy
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

5.  Ultrasound markers in early diagnosis of asymptomatic chronic hepatitis. A prospective study.

Authors:  Mihai Lazăr; Ecaterina Constanţa Barbu; Cristina Emilia Chiţu; Marius Ştefan; Daniela Adriana Ion
Journal:  Germs       Date:  2022-03-31

Review 6.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

7.  Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.

Authors:  Catherine O'Doherty; Alexander Favorov; Shirley Heggarty; Colin Graham; Olga Favorova; Michael Ochs; Stanley Hawkins; Michael Hutchinson; Killian O'Rourke; Koen Vandenbroeck
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

Review 8.  Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.

Authors:  Julie R Jonsson; David M Purdie; Andrew D Clouston; Elizabeth E Powell
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; modulating influence of TNF-α cytokine genetic polymorphism.

Authors:  Ali Mandegary; Arastoo Saeedi; Aziz Eftekhari; Vahideh Montazeri; Elham Sharif
Journal:  Daru       Date:  2013-04-08       Impact factor: 3.117

10.  Influence of Genetic Polymorphisms of Tumor Necrosis Factor Alpha and Interleukin 10 Genes on the Risk of Liver Cirrhosis in HIV-HCV Coinfected Patients.

Authors:  Sara Corchado; Mercedes Márquez; Montserrat Montes de Oca; Paula Romero-Cores; Clotilde Fernández-Gutiérrez; José-Antonio Girón-González
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.